X-linked Hypophosphatemia (XLH) Market: Overview
- X-linked hypophosphatemia (XLH) is inherited disorder characterized by reduced or low phosphate levels due to abnormal processing in the kidneys. This results in loss of phosphate in the urine leading to softening or weakening of bones.
Read Report Overview -
https://www.transparencymarketresearch.com/xlinked-hypophosphatemia-xlh-market.html
- The disorder is usually diagnosed in children with symptoms such as bent or bowed legs, severe dental & bone pain, and short stature. This is due to mutation in the PHEX gene on the X chromosome.
- The disorder is inherited in X-linked dominant manner as the gene responsible for the condition is located on the X chromosome. Also, women with X-linked hypophosphatemia (XLH) have 50% of chance to pass the disorder to her children.
- High-dose calcitriol, an active form of vitamin D and supplements of phosphate are primarily used as treatment regime. Other treatments include corrective surgery, growth hormones, and dental treatment.
Request Brochure of Report -
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=76804
Drivers of Global X-linked Hypophosphatemia (XLH) Market
- Rise in expenditure on research & development activities for genetic diseases, increase in penetration of market players focusing on the development of new therapeutic treatment for rare disease and collaborative efforts between pharmaceutical companies for developing therapies for genetic disorders are expected to drive the global X-linked hypophosphatemia (XLH) market
- Moreover, recent approval of drugs for X-linked hypophosphatemia (XLH) by regulatory authorities across the globe is projected to boost the growth of the market during the forecast period
- In December, 2018, Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd announced approval for Crysvita, burosumab injection by Heath Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients
- In February 2018, the European Commission granted marketing authorization for Crysvita allowing the drug to be marketed in 28 countries across Europe
- In January 2019, Kyowa Kirin Co., Ltd submitted an application for manufacturing and marketing approval with Japan's Ministry of Health, Labor and Welfare (MHLW) for burosumab
Request for TOC @
https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=76804
Pediatric Segment to Gain Market Share
- Based on age group, the global X-linked hypophosphatemia (XLH) market can be classified into pediatric, adults, and elderly
- The pediatric segment is anticipated to gain significant share in the global X-linked hypophosphatemia (XLH) market during the forecast period, owing to increase in prevalence of genetic disorders among children, rise in emphasis on early diagnosis & treatment of disorders among children, and significant increase in availability of therapeutic options of treatment of rare disorders among children
Hospital Pharmacies Segment to Exhibit Significant Growth
- Based on distribution channel, the global X-linked hypophosphatemia (XLH) market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies
- The hospital pharmacies segment is anticipated to gain significant share in the global X-linked hypophosphatemia (XLH) market during the forecast period, owing to rise in demand for pharmaceuticals and drug supplies for children
Pre Book X-linked Hypophosphatemia (XLH) Market Report at
https://www.transparencymarketresearch.com/checkout.php?rep_id=76804<ype=S
North America to Hold Major Share of Global X-linked Hypophosphatemia (XLH) Market
- North America is projected to account for a prominent share of the global X-linked hypophosphatemia (XLH) market during the forecast period. Growth of the X-linked hypophosphatemia (XLH) market in the region can be ascribed to the product approvals by the Food and Drug Administration (FDA) and increase in awareness about available treatment for genetic disorders.
- In April 2018, the FDA approved Crysvita for the treatment of X-linked hypophosphatemia (XLH) patients in the U.S.
Key Players in Global X-linked Hypophosphatemia (XLH) Market
Major players operating in the global X-linked hypophosphatemia (XLH) market are:
- Ultragenyx Pharmaceutical
- Kyowa Kirin Co., Ltd
More Trending Reports by Transparency Market Research –
AR in healthcare Market:
Renal Anemia Treatment Market:
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
